Skip to main content

Caboxen 20 mg & 80 mg ( Cabozantinib)

Cabozantinib, the active ingredient identified for Caboxen, is a targeted anticancer medicine that belongs to the tyrosine kinase inhibitor (TKI) class. It works by blocking several proteins involved in cancer-cell signaling, tumor growth, survival, movement, and the formation of new blood vessels.

Unlike conventional chemotherapy medicines that generally affect rapidly dividing cells, cabozantinib targets selected molecular pathways that cancer cells may use to grow and progress. Its multi-target activity makes it an important treatment option in certain cancer settings.

Cabozantinib is used for specific cancers according to the formulation and applicable regulatory approval. Its effectiveness and safety depend on the patient’s diagnosis, treatment history, and individual medical condition.

What Are Tyrosine Kinases?

Tyrosine kinases are enzymes that help regulate communication within cells. They act as molecular switches that control several important biological activities.

These enzymes participate in:

  • Cell growth and division.
  • Cell survival.
  • Cellular movement.
  • Tissue development.
  • Formation of new blood vessels.
  • Communication between cells.
  • Responses to external growth signals.

In healthy tissues, these processes are carefully regulated. However, certain cancers develop abnormal signaling pathways that allow cells to grow and survive without normal control.

Some tumors also stimulate surrounding blood vessels to develop and supply the growing cancer with oxygen and nutrients.

Cabozantinib works by inhibiting selected receptor tyrosine kinases involved in these processes.

Cabozantinib as a Multi-Targeted Tyrosine Kinase Inhibitor

Cabozantinib is described as a multi-targeted medicine because it acts on several molecular targets rather than focusing on only one protein.

Its important targets include:

  • MET.
  • VEGFR1.
  • VEGFR2.
  • VEGFR3.
  • AXL.
  • RET.
  • KIT.
  • Other receptor tyrosine kinases.

These targets participate in different signaling pathways associated with cancer development.

By inhibiting their activity, cabozantinib can interfere with multiple biological processes that support tumor growth and progression.

1. How Cabozantinib Inhibits VEGF Receptors

Vascular endothelial growth factor receptors (VEGFRs) are involved in angiogenesis, the formation of new blood vessels.

Tumors need oxygen and nutrients to grow. As a tumor develops, it may stimulate the formation of new blood vessels that supply these essential resources.

This process is known as tumor angiogenesis.

VEGF signaling helps regulate the development of these blood vessels. Increased signaling through VEGF receptors can support tumor-associated blood-vessel formation.

Cabozantinib inhibits VEGF receptor activity, interfering with signaling involved in angiogenesis.

Why Is VEGFR Inhibition Important?

Blocking VEGF receptor signaling may:

  • Interfere with tumor-associated blood-vessel formation.
  • Reduce signaling that supports angiogenesis.
  • Disrupt pathways involved in tumor growth.
  • Affect the tumor environment.

This mechanism is one of the important components of cabozantinib’s anticancer activity.

However, inhibiting angiogenesis does not guarantee that a tumor will stop growing or disappear. Treatment response varies between patients.

2. How Cabozantinib Inhibits MET

MET is a receptor tyrosine kinase involved in cellular growth, survival, movement, and tissue development.

Abnormal MET signaling has been associated with several cancer-related processes.

In certain tumors, increased MET activity may contribute to:

  • Cancer-cell growth.
  • Cell survival.
  • Tumor invasion.
  • Cellular migration.
  • Disease progression.
  • Changes associated with treatment resistance.

Cabozantinib inhibits MET signaling and may interfere with these processes.

The Role of MET in Cancer

When MET signaling becomes abnormal, cancer cells may receive signals that support their survival and movement.

By inhibiting MET, cabozantinib acts on a pathway that may contribute to tumor progression.

Its activity against MET works alongside its effects on other molecular targets.

3. How Cabozantinib Inhibits AXL

AXL is another receptor tyrosine kinase involved in cellular signaling.

It participates in processes such as cell survival, migration, invasion, and interactions between tumor cells and their surrounding environment.

Abnormal AXL activity has been associated with cancer progression and mechanisms that may contribute to treatment resistance.

Cabozantinib inhibits AXL, providing another component of its multi-target pharmacological activity.

Why Is AXL Important?

AXL signaling can influence how cancer cells survive and interact with surrounding tissues.

Its inhibition may interfere with certain biological processes associated with tumor development.

The combined activity against AXL, MET, and VEGF receptors distinguishes cabozantinib from medicines that primarily target a single signaling pathway.

4. The Role of RET and KIT

Cabozantinib also inhibits other receptor tyrosine kinases, including RET and KIT.

RET

RET is involved in cellular signaling, growth, and development. Changes in RET signaling can be relevant to certain cancers.

Cabozantinib’s activity against RET contributes to its broader molecular target profile.

KIT

KIT is a receptor tyrosine kinase involved in cellular growth, survival, and development.

Its inhibition contributes to the pharmacological activity of cabozantinib, although the clinical relevance of individual targets depends on the cancer type and treatment setting.

5. How Multiple Pathway Inhibition Supports Cancer Treatment

Cancer development is complex. Tumors can use several signaling pathways simultaneously to support their growth and survival.

Targeting only one pathway may not interfere with every mechanism involved in cancer progression.

Cabozantinib inhibits multiple receptor tyrosine kinases, including proteins involved in angiogenesis and tumor-cell signaling.

Its combined activity against MET, VEGFR, and AXL is particularly important to its pharmacological profile.

This multi-target approach may interfere with:

  • Tumor-associated angiogenesis.
  • Cancer-cell survival signaling.
  • Cellular migration and invasion.
  • Growth-related signaling pathways.
  • Interactions between tumors and surrounding tissues.

The clinical benefits depend on the cancer being treated and the patient’s response to therapy.

Which Cancers May Be Treated With Cabozantinib?

Cabozantinib has established uses in selected cancer-treatment settings. The approved indications differ according to the formulation and regulatory authority.

Renal Cell Carcinoma

Renal cell carcinoma is a type of kidney cancer.

Cabozantinib tablets are used in specified settings for advanced renal cell carcinoma. Treatment may involve cabozantinib alone or in combination with another anticancer medicine, depending on the applicable approval and treatment plan.

Hepatocellular Carcinoma

Hepatocellular carcinoma is a primary liver cancer.

Cabozantinib tablets are used in certain patients who have previously received specified treatment.

Differentiated Thyroid Cancer

Certain patients with differentiated thyroid cancer may receive cabozantinib tablets when their disease meets defined treatment criteria, including specific requirements involving previous treatment and radioiodine status.

Neuroendocrine Tumors

Cabozantinib tablets have an approved role in certain previously treated, unresectable, locally advanced, or metastatic well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors in jurisdictions where this indication is authorized.

Medullary Thyroid Cancer

The cabozantinib capsule formulation has a separate established indication for progressive metastatic medullary thyroid cancer under its applicable regulatory approval.

These uses should not be assumed to apply to every cabozantinib formulation or automatically attributed to Caboxen without confirmation of its product-specific regulatory status.

How Does Cabozantinib Affect Tumor Growth?

Cabozantinib interferes with several signaling pathways that contribute to cancer progression.

Its inhibition of VEGF receptors affects signaling associated with blood-vessel development. Its inhibition of MET and AXL affects pathways involved in cell survival, movement, and invasion.

Together, these actions may interfere with biological processes that support tumor development.

However, cabozantinib does not work in exactly the same way in every patient.

Treatment response depends on:

  • Cancer type.
  • Tumor characteristics.
  • Molecular signaling activity.
  • Disease stage.
  • Previous cancer treatment.
  • Prescribed dose.
  • Individual treatment tolerance.
  • Other medical conditions.

Some patients may experience disease control, while others may have limited benefit or develop disease progression despite treatment.

Is Cabozantinib a Conventional Chemotherapy Medicine?

Cabozantinib is classified as a targeted anticancer medicine rather than a conventional cytotoxic chemotherapy drug.

Conventional chemotherapy generally affects cells that divide rapidly. Targeted medicines are designed to interfere with selected proteins or pathways involved in disease development.

Cabozantinib specifically inhibits several receptor tyrosine kinases.

Although its mechanism differs from conventional chemotherapy, it can still cause significant adverse reactions and requires appropriate medical supervision.

Targeted therapy does not mean that a medicine is free from serious side effects.

How Long Does Cabozantinib Take to Work?

The time required to observe a response to cabozantinib varies between patients.

Treatment response depends on the cancer type, disease characteristics, previous therapies, and individual biological factors.

Healthcare professionals generally assess treatment progress through clinical evaluations, laboratory investigations, and appropriate imaging examinations.

Patients should not judge treatment effectiveness based only on how they feel during the first days or weeks.

The treating oncologist determines whether treatment is providing sufficient benefit and whether it should be continued.

Does Cabozantinib Cure Cancer?

Cabozantinib is not a guaranteed cure for cancer.

It is used to control certain cancers in specific treatment settings. Depending on the disease and treatment response, it may help delay progression or provide disease control.

The treatment goal varies according to the diagnosis, stage, previous treatment, and individual circumstances.

Patients should discuss realistic treatment expectations with their oncology team.

Why Is Medical Monitoring Important?

Cabozantinib affects several biological pathways that are also involved in normal body functions.

Consequently, treatment can cause adverse reactions that require monitoring.

Healthcare professionals may monitor:

  • Blood pressure.
  • Liver function.
  • Kidney function.
  • Urine protein.
  • Blood tests.
  • Gastrointestinal symptoms.
  • Skin reactions.
  • Bleeding symptoms.
  • Dental health.
  • General treatment tolerance.

Regular monitoring helps identify complications and supports decisions about dose modification or treatment interruption.

Important Safety Considerations

Cabozantinib can cause serious adverse reactions, including:

  • Hypertension.
  • Severe bleeding.
  • Blood clots.
  • Gastrointestinal perforation.
  • Fistula formation.
  • Severe diarrhea.
  • Hand-foot skin reactions.
  • Impaired wound healing.
  • Osteonecrosis of the jaw.
  • Proteinuria.
  • Embryo-fetal toxicity.

Patients should promptly report concerning symptoms to their healthcare professionals.

Severe abdominal pain, significant bleeding, chest pain, sudden difficulty breathing, or sudden neurological symptoms may require urgent medical attention.

Does Cabozantinib Work the Same Way in Every Formulation?

Cabozantinib tablets and capsules contain the same active ingredient but have important pharmaceutical differences.

The reference tablet and capsule products have different strengths, dosing schedules, fasting requirements, and approved indications. They are not bioequivalent and should not be substituted for one another.

The exact dosage form of Caboxen must be confirmed before applying any formulation-specific information.

Caboxen is presented in 20 mg and 80 mg strengths, but those strengths alone do not establish whether it is a capsule or tablet.

Conclusion

Cabozantinib works by inhibiting several receptor tyrosine kinases involved in cancer-related signaling. Its activity against MET, VEGF receptors, AXL, RET, and KIT contributes to its multi-target anticancer mechanism.

By interfering with pathways associated with tumor growth, cell survival, migration, and blood-vessel formation, cabozantinib may help control certain cancers in appropriate treatment settings.

Its use requires accurate product identification, formulation-specific prescribing instructions, medical supervision, and regular monitoring.

Caboxen should only be used under the supervision of a qualified healthcare professional after its exact formulation, product identity, and appropriate prescribing information have been confirmed.